What are the off‑label temperature excursion limits for storing Tremfya (guselkumab)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 13, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Off-Label Temperature Excursion Limits for Tremfya

The FDA-approved labeling for Tremfya does not specify any allowable off-label temperature excursion limits beyond the standard storage requirement of 2°C to 8°C (36°F to 46°F) in the refrigerator. 1

Official Storage Requirements

The FDA label explicitly states 1:

  • Store in refrigerator at 2°C to 8°C (36°F to 46°F)
  • Do not freeze
  • Do not shake
  • Store in original carton to protect from light
  • Discard any unused portion (preservative-free)

Critical Gap in Available Information

No manufacturer-provided data exists in the FDA labeling regarding acceptable room temperature excursions for Tremfya. This is a significant limitation, as many other biologic medications have documented allowable periods at room temperature 1.

What This Means Clinically

Since Tremfya is a monoclonal antibody (fully human IgG1λ) targeting IL-23p19 2, it is susceptible to temperature-induced degradation like other biologics. Without manufacturer-validated temperature excursion data:

  • Any deviation from 2°C to 8°C storage is technically off-label and not supported by stability data
  • Product exposed to temperatures outside this range should be evaluated on a case-by-case basis
  • Contact the manufacturer (Janssen Biotech at 1-800-526-7736) directly for specific temperature excursion guidance 1

Common Pitfalls to Avoid

Do not assume Tremfya follows the same temperature excursion allowances as other biologics. While research shows that 87% of refrigerated medications have some documented room temperature stability 3, and comprehensive temperature excursion management programs exist for biopharmaceuticals 4, Tremfya's specific excursion limits are not published in its FDA labeling.

The absence of this information in the prescribing information means:

  • You cannot extrapolate from other IL-23 inhibitors
  • Standard "room temperature" assumptions (20-25°C for limited periods) are not validated for this product
  • Any temperature excursion requires manufacturer consultation for product viability assessment

If temperature excursion occurs, do not use the product without explicit manufacturer approval, as the FDA label provides no safety margin for deviations 1.

References

Research

Guselkumab: Pediatric First Approval.

Paediatric drugs, 2026

Research

Allowable room temperature excursions for refrigerated medications: A 20-year review.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2022

Related Questions

What are the recommended temperature excursion limits for Tremfya (guselkumab) prefilled syringes?
What is the recommended dosing schedule for guselkumab (Tremfya)?
Can Tremfya (guselkumab) cause urinary tract infections?
How long can Retacrit (epoetin alfa) be kept at room temperature outside the refrigerator?
How long can Stalara (brand name) stay unrefrigerated?
Given a patient with DLCO (uncorrected) 72% predicted, DLCO (corrected) 67% predicted, DL/VA 64% predicted, alveolar volume (VA) 103% predicted, slow vital capacity (SVC) 94% predicted, inspiratory capacity (IC) 70% predicted, and total lung capacity (TLC) 127% predicted, what is the most likely diagnosis and appropriate treatment plan?
Based on the pulmonary function test showing increased total lung capacity, reduced diffusing capacity, low diffusing capacity per alveolar volume (DL/VA), and decreased inspiratory capacity, is this consistent with chronic obstructive pulmonary disease (COPD)?
Is water immersion preferred over air insufflation for routine colonoscopy in adults?
A patient on olanzapine 7.5 mg daily has nipple discharge (galactorrhea) with a serum prolactin of 17.8 ng/mL; how should this be managed?
In a patient with schizoaffective disorder with depressive features, should I start quetiapine (Seroquel) or risperidone, and what are the appropriate dosing and monitoring considerations?
When performing a lumbar fusion, does decompressing the adjacent level(s) compromise the stability of the fused segment, even if only one level is decompressed?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.